Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.72 |
| ▸ | IGF2R | P11717 | 4/20 | 0.55 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | UMPS | P11172 | 2/20 | 0.41 |
| ▸ | ATIC | P31939 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29323929 | 1.00 | FBP1 (0.72) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL29324521 | 1.00 | FBP1 (0.72) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL13857406 | 1.00 | FBP1 (0.72) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL14985153 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL10064521 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL23960812 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL14503325 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL15765675 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL18294135 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL19454793 | 0.98 | FBP1 (0.75) | FBP1IGF2RAMDHD2P2RY2P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300083-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-04-06 | — | — | US | disclosed |
| US-20150263289-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300083-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | TLR4, TLR3, TLR1 | FBP1 963/4885IGF2R 730/4885AMDHD2 946/4885 |
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | FBP1 1153/4885IGF2R 747/4885AMDHD2 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.